MAAT MaaT Pharma SA
MaaT Pharma SA, a late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival. Its products pipeline includes MaaT013, that is in pivotal phase 3 clinical trial for the treatment of acute graft versus host diseases with gastrointestinal involvement; MaaT033, which is in phase 2b clinical trial for the improvement of survival at 12 months for patients with blood cancer receiving allogenic hematopoietic stem cell transplantation; and MaaT03X for the treatment of solid tumors, as well as MaaT034 that optimize immune checkpoint inhibitor treatment. MaaT Pharma SA was incorporated in 2014 and is headquartered in Lyon, France.…
Industry Peers
BiotechnologyKey Statistics
About MaaT Pharma (EPA: MAAT)
›
MaaT Pharma (EPA: MAAT) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 60 employees.
The shares were at 0.8700 EUR on 19 November 2026, down 77.9% over 52 weeks. Its 52-week range is 0.8700 EUR to 8.620 EUR, and it trades at the bottom of that range.
Its market capitalisation is 16.38M EUR.
MaaT Pharma reports revenue down 55.5% year over year.
Its debt exceeds its cash by 6.67M EUR, a debt-to-equity ratio of 8.56. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. One analyst covers the stock, with an average rating of Buy; their mean price target of 3.000 EUR is 244.8% above the current price.